ArticleFrontiers in aging neuroscience2026
PPARG as a central regulator of ferroptosis in Alzheimer's disease: integrated transcriptomic, single-cell, and experimental evidence.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, β-amyloid (Aβ) plaque accumulation, neurofibrillary tangle formation, and chronic neuroinflammation. Increasing evidence suggests that ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, contributes to AD pathogenesis; however, its upstream regulatory mechanisms remain incompletely understood. Methods: Transcriptomic datasets from the Gene Expression Omnibus (GSE1297, GSE5281, and GSE157827) were analyzed to identify AD-associated differentially expressed genes (DEGs). Ferroptosis-related genes were obtained from curated databases and intersected with AD-associated DEGs. Protein-protein interaction (PPI) networks were constructed using the STRING database and analyzed via Cytoscape to identify key regulatory genes. Immune cell infiltration was quantified using CIBERSORT. Molecular docking was performed to evaluate ligand-PPARG binding. Functional validation was conducted using Results: A total of 50 reproducible differentially expressed genes (DEGs) were identified across two independent transcriptomic datasets, of which 24 genes were associated with ferroptosis. Network analysis consistently identified peroxisome proliferator-activated receptor gamma (PPARG) as a central hub gene within the ferroptosis regulatory network. Immune infiltration analysis revealed increased M2 macrophage abundance in AD tissues, suggesting an association between ferroptosis-related gene expression and immune-related transcriptional signatures. Molecular docking demonstrated stable ligand binding to PPARG with a binding affinity of -5.6 kcal/mol, supported by hydrogen-bond and hydrophobic interactions. Experimental validation confirmed that PPARG modulation significantly influenced ferroptosis-associated neuronal injury both Conclusion: These findings identify PPARG as a key regulator linking ferroptosis and neuroinflammation in Alzheimer's disease. Targeting PPARG-mediated ferroptotic pathways may therefore represent a promising therapeutic strategy for mitigating neurodegeneration in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.